Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Age-related differences in clinical outcomes among hospitalized recipients of CAR-T cell therapy: A national readmission database analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

MKMuhammad Atif KhanFKFaiza Humayun KhanNANausheen Ahmed

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows differences in clinical outcomes and complications in hospitalized CAR-T patients by age, indicating older adults may need tailored care.

Key Points

  • This research investigates age-related differences in clinical outcomes following CAR-T therapy among hospitalized patients.
  • Retrospective cohort study using 2021–2022 National Readmission Database (NRD)
  • Analyzed adults (≥18 years) hospitalized for CAR-T therapy
  • Patients stratified into age groups: ≥65 years and <65 years
  • Outcomes included in-hospital mortality, length of stay, and treatment-related complications
  • Used Rao-Scott chi-square tests and Kruskal-Wallis tests for comparisons
  • Total of 3,519 weighted hospitalizations analyzed
  • Older patients (≥65 years) exhibited higher rates of chronic kidney disease and hypertension
  • In-hospital mortality was higher in older patients (4.8% vs 3.0%) but not statistically significant
  • Older adults had significantly more cases of encephalopathy and cytokine release syndrome
  • Length of stay was similar between age groups, with a median of 14 days

Cite This Study

Khan et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd13https://doi.org/10.1182/blood-2025-7841
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of age on outcomes of CAR-T cell therapy in multiple myeloma, DLBCL, and follicular lymphoma: A real-world multi-center propensity-matched analysis2025
  2. 2Comparative outcomes of CAR-T therapy in elderly (≥70 Years) versus younger (&amp;lt;70 Years) patients with relapsed/refractory multiple myeloma: A real-world propensity-matched cohort study2025
  3. 3CAR-T in the older adults: Real-world survival and toxicity in patients ≥ 75 years with relapsed/refractory multiple myeloma.2026
  4. 4Geriatric Assessment in Patients Aged 70 Years and Older Considered for CAR T-Cell Therapy: A Retrospective Study2026
  5. 5Anti‐<scp>CD19</scp> chimeric antigen receptor T‐cell therapy in older patients with relapsed or refractory large B‐cell lymphoma: A multicenter study2024 · 10 citations